| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.6M | — | — |
| R&D Expense | $13.6M | — | -52.8% |
| SG&A Expense | $5.2M | — | -10.9% |
| Operating Income | -$14.2M | — | +59.0% |
| Net Income | -$10.4M | — | +67.6% |
| EPS (Basic) | -$0.13 | — | +69.0% |
| EPS (Diluted) | -$0.13 | — | +69.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $21.8M | -38.3% | -46.0% |
| Short-term Investments | $59.8M | -12.0% | +1.7% |
| Current Assets | $84.6M | -20.0% | -17.4% |
| Total Assets | $119.6M | -15.3% | -15.3% |
| Current Liabilities | $41.7M | -21.3% | +110.8% |
| Total Liabilities | $59.5M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$21.7M | — | +36.7% |
| Capital Expenditures | $0 | — | -100.0% |
| Investing Cash Flow | $8.5M | — | -86.3% |
| Financing Cash Flow | -$314K | — | -96.3% |
| Free Cash Flow | -$21.7M | — | +36.7% |
| +56.1% |
| Stockholders' Equity | $60.2M | -12.3% | -41.7% |